platelet-rich plasma
Overview
Platelet-rich plasma (PRP) is an autologous blood-derived biologic preparation enriched in platelets and, consequently, in platelet-associated growth factors and signaling molecules. In biomedical research and clinical practice, PRP is investigated as a regenerative adjunct intended to support tissue repair, angiogenesis, and wound healing by delivering concentrated endogenous mediators at the site of injury.
Because PRP is derived from the patient’s own blood, it is generally studied as a minimally invasive therapeutic platform rather than a conventional drug. Recent research has explored its use across diverse regenerative settings, including chronic wounds, skin graft support, adipose tissue regeneration, spinal cord injury, and musculoskeletal conditions such as lumbar disc herniation. Mechanistically, PRP is often discussed in relation to pathways involving vascular endothelial growth factor A (VEGFA), PTEN, Akt1, and Mechanistic target of rapamycin (mTOR), as well as in combination with mesenchymal stem cell, extracellular vesicle-based approaches, and engineered biomaterials.
Recent Publications Summary
Recent studies have continued to evaluate platelet-rich plasma (PRP) as an adjunctive regenerative therapy across orthopedic, wound-healing, and reconstructive settings. In obese individuals with knee osteoarthritis, a retrospective comparison suggested that intra-articular PRP was associated with better clinical outcomes than hyaluronic acid, including lower rates of arthroplasty, improved range of motion, and better VAS and WOMAC scores, although the hazard reduction for arthroplasty did not reach statistical significance in Cox analysis 42584701Aug. A separate protocol described a pragmatic randomized trial testing ultrasound-guided PRP injection plus physiotherapy versus physiotherapy alone for L5/S1 lumbar disc herniation, reflecting ongoing interest in PRP as part of conservative management for spinal pain and neurologic symptoms 42023259Apr.
Several publications focused on PRP in wound repair and tissue regeneration. In diabetic rat full-thickness wounds, PRP combined with a biodegradable PGS/PLA scaffold accelerated wound closure, increased fibroblast and blood vessel formation, reduced inflammatory cell infiltration, and improved collagen deposition and biomechanical properties compared with scaffold alone or PRP alone 41861435Mar. In dogs with experimentally induced full-thickness skin wounds, PRP-based treatments reduced wound size and increased contraction versus controls, with the PRP/chitosan-silver nanoparticle combination producing the greatest wound reduction over 21 days and accompanying histopathologic and immunohistochemical evidence of enhanced repair 42484703Jul. A case report of a refractory venous leg ulcer after multiple failed skin grafts also described substantial ulcer reduction and eventual complete healing after six PRP sessions as part of multidisciplinary care 42367130Jun.
PRP has also been investigated in more complex reconstructive and orthopedic applications. A retrospective cohort study evaluated a modified Masquelet technique augmented with PRP-autologous iliac bone graft mixture for large post-traumatic infected bone defects, aiming to assess bone healing, pain, functional recovery, and quality of life 42330693Jun. In another experimental study, PRP was compared with plasma gel for fat graft survival under cigarette smoke exposure, addressing whether PRP-derived products can counter impaired graft viability in compromised tissue environments 42241808Jun. Additionally, a study in spinal cord injury examined PRP-primed bone marrow mesenchymal stem cell-derived exosomes and reported effects on neuronal apoptosis, autophagy, and nerve regeneration through the miR-29a-3p/PTEN/PI3K/Akt/mTOR axis, indicating that PRP may enhance the therapeutic profile of mesenchymal stem cell-derived extracellular vesicles 42165939May.
Mechanistic and formulation-oriented work further highlighted PRP’s use in combination platforms. An injectable thermosensitive hydrogel incorporating dopamine-based nanoparticles and PRP was designed for osteoarthritis and was reported to suppress reactive oxygen species generation, inhibit ferroptosis, and promote macrophage M2 polarization, suggesting a multifunctional anti-inflammatory strategy for joint disease 42447220Jul. A commentary on biologics in plastic surgery emphasized the need for standardized reporting of PRP preparation and composition, noting that heterogeneous methodology limits evidence synthesis and proposing broader adoption of minimum-information reporting standards 42054980Apr.
What Changes, What Holds
1. PRP may outperform hyaluronic acid in obese knee osteoarthritis, but the comparative advantage is not yet settled
NEW DIRECTION In obese patients with knee osteoarthritis, PRP is being positioned not just as an adjunctive regenerative biologic but as a candidate alternative to a common intra-articular comparator, with signals for better symptoms and function and possible delay of arthroplasty 42584701Aug. That extends the baseline’s musculoskeletal use, but the cohort design and non-significant arthroplasty hazard keep this as suggestive rather than practice-changing. The lumbar disc herniation protocol adds only that PRP remains under active conservative-management testing 42023259Apr.
2. PRP gains support as a wound-healing enhancer in difficult tissue environments
REINFORCES PRP again reads as a pro-repair adjunct rather than a stand-alone therapy, with evidence that it can accelerate closure, improve granulation and collagen organization, and help refractory ulcers heal when layered onto scaffolds or multidisciplinary care 41861435Mar42367130Jun. Nothing here overturns the baseline; instead, it sharpens the expectation that PRP’s main value lies in boosting local repair biology in compromised wounds, especially when combined with biomaterials or other supportive measures.
3. PRP may improve the performance of other regenerative constructs in reconstruction and nerve repair
REINFORCES PRP’s role broadens here as an enabling additive for reconstructive strategies, from bone-defect repair to graft survival and exosome-based neuroregeneration 42330693Jun42241808Jun42165939May. That is consistent with the Overview’s framing of PRP as a partner to stem cells, extracellular vesicles, and engineered materials rather than a replacement for them. The new work mainly strengthens the idea that PRP can tune host response and regenerative yield across difficult healing settings.
4. Standardization now looks essential if PRP studies are to be compared and translated
METHOD The most consequential message is methodological: PRP research is being constrained less by lack of targets than by inconsistent preparation and reporting, which makes cross-study synthesis unreliable and pushes the field toward minimum-information standards 42054980Apr. The hydrogel and nanoparticle work also reinforces that formulation design is now central to PRP experimentation 42447220Jul. This changes how PRP should be studied and reported, not what its core biological role is understood to be.
Overview update candidates: PRP as a comparator in obese knee osteoarthritis; PRP-enhanced multimodal wound repair; PRP as an adjunct to bone; graft; and exosome-based reconstruction; standardized reporting of PRP preparation and composition.
platelet-rich plasma
Background Contexts
In the literature, the biological baseline, pathological conditions, or disease models commonly surrounding platelet-rich plasma are described as follows:
- osteoarthritis (Disease) — 2 papers: PMIDs 42447220, 42276262
- alopecia (Disease) — 1 paper: PMIDs 42493806
- anti-inflammatory drug (Therapy) — 1 paper: PMIDs 42023259
- Cell-free tissue engineering (Other) — 1 paper: PMIDs 42070602
- Chronic lower-extremity ulcers (Disease) — 1 paper: PMIDs 42367130
- CLINIC-STRA-SVF (Other) — 1 paper: PMIDs 42054980
- exercise-based physiotherapy (Therapy) — 1 paper: PMIDs 42023259
- Full-thickness skin defects (Disease) — 1 paper: PMIDs 42189841
- growth factor (Protein) — 1 paper: PMIDs 42484703
- Infected Bone Defect (Disease) — 1 paper: PMIDs 42330693
- infection (Disease) — 1 paper: PMIDs 42484703
- Janus kinases (Protein) — 1 paper: PMIDs 42414040
Methodologies & Technologies Used
Researchers utilize the following experimental methods, imaging platforms, computational models, or biological reagents to study platelet-rich plasma:
- debridement (Other) — 2 papers: PMIDs 42367130, 42330693
- Actin gamma 2, smooth muscle (Protein) — 1 paper: PMIDs 42484703
- Alexa Fluor 488 CD62p (Other) — 1 paper: PMIDs 42414040
- Alexa Fluor 568 Annexin-V (Other) — 1 paper: PMIDs 42414040
- Alexa Fluor 647 PAC-1 (Other) — 1 paper: PMIDs 42414040
- antibiotic (Therapy) — 1 paper: PMIDs 42330693
- Autologous Iliac Bone Graft (Therapy) — 1 paper: PMIDs 42330693
- bFGF/VEGFA@PRP hydrogel (Technology) — 1 paper: PMIDs 42189841
- Bone Bridge Preservation (Biological Process) — 1 paper: PMIDs 42330693
- bone defect (Disease) — 1 paper: PMIDs 42330693
- Bulk release experiments (Technology) — 1 paper: PMIDs 42276262
- Cement Spacer Removal (Biological Process) — 1 paper: PMIDs 42330693
Molecular Interventions & Targets
The primary molecular pathways, regulatory genes, enzymes, or therapeutic agents actively targeted and manipulated in relation to platelet-rich plasma include:
- mesenchymal stem cell (Cellular Component) — 2 papers: PMIDs 42165939, 42054980
- basic fibroblast growth factor (Protein) — 1 paper: PMIDs 42189841
- chitosan (Chemical) — 1 paper: PMIDs 42484703
- Composition (Clinical Metric) — 1 paper: PMIDs 42493806
- extracellular vesicle (Cellular Component) — 1 paper: PMIDs 42165939
- growth factor (Protein) — 1 paper: PMIDs 42493806
- HAMA/SFMA/PRP Composite Bioactive Hydrogels (Other) — 1 paper: PMIDs 42070602
- Mechanistic target of rapamycin (mTOR) (Protein) — 1 paper: PMIDs 42165939
- miR-29a-3p (Gene) — 1 paper: PMIDs 42165939
- Performance (Clinical Metric) — 1 paper: PMIDs 42493806
- Phosphatase and Tensin Homolog (PTEN) (Protein) — 1 paper: PMIDs 42165939
- PIK3CB (Protein) — 1 paper: PMIDs 42165939
Observed Outcomes & Phenotypes
The phenotypic changes, physiological endpoints, or clinical metrics observed and measured in connection with platelet-rich plasma include:
- collagen deposition (Clinical Metric) — 2 papers: PMIDs 42484703, 41861435
- 2 sigma (Clinical Metric) — 1 paper: PMIDs 42584701
- Actin gamma 2, smooth muscle (Protein) — 1 paper: PMIDs 42484703
- Adipose Tissue Regeneration (Biological Process) — 1 paper: PMIDs 42070602
- arthroplasty (Therapy) — 1 paper: PMIDs 42584701
- autophagy pathways (Biological Process) — 1 paper: PMIDs 42165939
- bioavailability and therapeutic efficacy (Clinical Metric) — 1 paper: PMIDs 42165939
- blood vessel (Cellular Component) — 1 paper: PMIDs 41861435
- Bone Healing Rate (Clinical Metric) — 1 paper: PMIDs 42330693
- Bone Healing Time (Clinical Metric) — 1 paper: PMIDs 42330693
- Bone Union (Biological Process) — 1 paper: PMIDs 42330693
- Chitosan-Capped Silver Nanoparticles (Chemical) — 1 paper: PMIDs 42484703
General Takeaways & Clinical Potentials
The high-level concepts, clinical translations, and overarching conclusions proposed in the research surrounding platelet-rich plasma are summarized below:
- Adipose Tissue Regeneration (Biological Process) — 1 paper: PMIDs 42070602
- angiogenesis (Biological Process) — 1 paper: PMIDs 41861435
- biological efficacy of PRP (Other) — 1 paper: PMIDs 42023259
- chitosan (Chemical) — 1 paper: PMIDs 42484703
- collagen deposition (Clinical Metric) — 1 paper: PMIDs 41861435
- collagen remodeling (Biological Process) — 1 paper: PMIDs 42484703
- comparative effectiveness estimates (Clinical Metric) — 1 paper: PMIDs 42493806
- complex, refractory ulcers (Disease) — 1 paper: PMIDs 42367130
- Dosing (Other) — 1 paper: PMIDs 42493806
- epithelial regeneration (Biological Process) — 1 paper: PMIDs 42484703
- hypoxic-microenvironment-responsive therapeutic strategy (Therapy) — 1 paper: PMIDs 42165939
- MIBO checklist (Other) — 1 paper: PMIDs 42054980